Peptide Biomaterials for Pharmaceutical Applications

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 1248

Special Issue Editors


E-Mail Website
Guest Editor
Deparment of Chemical & Biological Sciences, Universidad de las Américas Puebla, San Andrés Cholula, Mexico
Interests: nanomedicine; nanomaterials; nanotoxicology; drug delivery systems; biomaterials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Deparment of Chemical & Biological Sciences, Universidad de las Américas Puebla, San Andrés Cholula, Mexico
Interests: nanomedicine; biomaterials; drug delivery systems; pharmaceutical technology; cosmetic development

E-Mail Website
Guest Editor
Faculty of Pharmacy, Autonomous University of Morelos State, Cuernavaca, Mexico
Interests: drug delivery systems; nanocarriers; particle engineering; inhalation therapy; biomaterials

Special Issue Information

Dear Colleagues,

Peptides are small molecules consisting of a couple or several amino acids coupled through peptide bonds. They have important uses in living organisms as hormones and chemical messengers and can be used for the design of novel therapies and innovative pharmaceuticals. The emergence of innovative engineered proteins, peptide biopolymers and peptide-based biomaterials for novel drug delivery, drug development, biosensors or tissue regeneration has encountered important challenges, such as their chemical and physical fragility (rapid degradation), poor or limited solubility and scarce permeability.

The aim of this Special Issue is to offer to our readers an updated and comprehensive glimpse of the recent in vitro and in vivo uses of peptide-based biomaterials for pharmaceutical applications. We invite full papers, communications and reviews covering topics related to the keywords below.

Dr. Miguel Mendez-Rojas
Dr. Sergio Alberto Bernal Chavez
Dr. Sergio Alcalá Alcalá
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peptides
  • pharmaceutical applications
  • nanomedicine
  • peptide materials
  • peptide conjugates
  • drug delivery systems
  • nanocarriers
  • biologics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3239 KiB  
Article
Efficacy of RADA16-Based Self-Assembling Peptides on Wound Healing: A Meta-Analysis of Preclinical Animal Studies
by Jiaju Lu, Liuting Chen, Zeyue Sun and Zhimou Yang
Pharmaceuticals 2025, 18(4), 526; https://doi.org/10.3390/ph18040526 - 3 Apr 2025
Viewed by 400
Abstract
Objectives: This analysis aims to provide evidence supporting the feasibility of clinical application of self-assembling peptides for skin wound healing. Methods: This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Web of Science, [...] Read more.
Objectives: This analysis aims to provide evidence supporting the feasibility of clinical application of self-assembling peptides for skin wound healing. Methods: This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Web of Science, and Cochrane Library were searched (up to June 17, 2024). The primary outcome, wound closure rate at 7 and 14 days post-injury, was pooled using a random-effects meta-analysis. The risk of bias (ROB) assessment and meta-analysis were performed using the Systematic Review Centre for Laboratory animal Experimentation (SYRCLE)’s ROB tool for animal studies and RevMan software. Results: A total of 502 unique records were identified from our search, with 12 experimental animal studies meeting the prespecified inclusion criteria (n = 272 animals). The RADA16 interventions promoted wound closure rate compared to controls (saline or no treatment group) in both diabetic and non-diabetic animal models (Mean Difference (MD) = 11.25, 95% Confidence Interval (CI): 5.73 to 16.78, p < 0.0001; MD = 9.48, 95% CI: 4.75 to 14.22, p < 0.0001 at 7 and 14 days post-injury, respectively). Healing was further enhanced using RADA16-based functional self-assembling peptides compared to RADA16 group in both diabetic and non-diabetic animal models (MD = 27.25, 95% CI: 22.68 to 31.83, p < 0.00001; MD = 29.11, 95% CI: 24.30 to 33.91, p < 0.00001 at 7 and 14 days after injury, respectively). The ROB was uncertain for most studies due to insufficient reporting. Conclusions: RADA16-based self-assembling peptides, particularly those modified with functional peptide motifs, represent a promising treatment for non-diabetic and diabetic wounds in pre-clinical studies, and translation to the clinical domain appears warranted. Full article
(This article belongs to the Special Issue Peptide Biomaterials for Pharmaceutical Applications)
Show Figures

Graphical abstract

Back to TopTop